Antibe Investor Presentation - February 2019

TSXV:ATE  
OTCQB:ATBPF
Leading Innovation in Pain & Inflammation

FEBRUARY 2019
Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com -

TSXV:ATE  
OTCQB:ATBPF
Forward-Looking Statements
This presentation contains forward-looking information and statements which constitute “forward-looking information” under Canadian securities
law and which may be material regarding, among other things, the Company’s beliefs, plans, objectives, estimates, intentions and expectations.
Specific forward-looking information in this document includes, but is not limited to, statements with respect to the Company’s future operating and
financial results, its research and development activities, its capital expenditure plans and the ability to execute on its future operating, investing and
financing strategies. These forward-looking information and statements, by their nature, necessarily involve risks and uncertainties that could cause
actual results to differ materially from those contemplated by these forward-looking statements. We consider the assumptions on which these
forward-looking statements are based to be reasonable, but caution the reader that these assumptions regarding future events, many of which are
beyond our control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect us. Additional information
regarding risk factors can be found in public disclosure records on SEDAR.
Our statements of “belief” in respect of our product and partner product candidates are based primarily upon our results derived to date from our
research and development program. We believe that we have a reasonable scientific basis upon which we have made such statements. It is not
possible, however, to predict, based upon in vitro and animal studies whether a new therapeutic agent or technology will be proved to be safe and/
or effective in humans. We cannot assure that the particular results expected by us will occur.
Any forward-looking statements and statements of “belief” represent our estimates only and should not be relied upon as representing our
estimates as of any subsequent date. Except as required by law, we do not assume any obligation to update any forward looking statements or
statements of “belief”. We disclaim any intention or obligation to update or revise any forward- looking statements or statements of “belief”,
whether as a result of new information, future events or otherwise. Nothing herein should be construed as an Offering of securities of the Company
in any jurisdictions.
Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !2

TSXV:ATE  
OTCQB:ATBPF
Antibe Therapeutics (“Antibe”) is a

public biotech company with a drug
platform of game-changing therapeutics
in pain and inflammation
Antibes Seen from the Salis Gardens Claude Monet (1840-1926)
Stock Symbols TSXV-ATE; OTCQB-ATBPF Shares Outstanding 243M
52 Week Trading Range $0.24 - $0.79 Market Capitalization $66M
Avg. Daily Volume* 562,000 Insider Ownership FULLY DILUTED 20%
*average of TSX-V daily volume over last 3 months

TSXV:ATE  
OTCQB:ATBPF
ATB-346: Lead Drug

TSXV:ATE  
OTCQB:ATBPF
NSAIDs: Large Market Opportunity
NSAIDs = Non-Steroidal   $11 Billion

Anti-Inflammatory Drugs
Global Market for NSAIDs1
Among the Most Widely  
Used Drugs in the World
GIis Pervasive
Damage
“The world needs a safer A Global

NSAID” - FDA, May 2010 Unmet Need
1. Global sales in 2014 (Evaluate Pharma)

TSXV:ATE  
OTCQB:ATBPF
NSAIDs Have a Blockbuster Pedigree

Of the sixteen drugs which hit $1 billion in sales in their first year 
GI damage and CV (top ten shown), two were for the GI-toxicity issue with NSAIDs:
safety from NSAIDs Product Company

Therapeutic US Sales in  
Category First Year
is “front and centre" Harvoni Gilead Hep C Antiviral $10.6B
on the radar screen Sovaldi Gilead Hep C Antiviral $9.0B
of physicians. Epclusa Gilead Hep C Antiviral $3.2
Celebrex Pharmacia NSAID $2.3B
Olysio J&J Hep C Antiviral $2.1B
Tecfidera Biogen MS $1.8B
Incivek Vertex Hep C Antiviral $1.7B
Ocrevus Roche MS $1.7B
Lipitor Pfizer Statin $1.5B
Vioxx Merck & Co NSAID $1.5B
Source: Evaluate Pharma

TSXV:ATE  
OTCQB:ATBPF
Addressing an Unmet Need…
ATB-346 was Better CV Safety

designed to deliver
both GI and The Need
cardiovascular safety
ATB-346
with non-addictive Naproxen
Better
pain relief. GI Safety
Non-selective
NSAIDs Celebrex
Several selective COX-2
Meloxicam WITHDRAWN
NSAIDs were withdrawn or
Bextra
discontinued due to
WITHDRAWN
increased risk of
Vioxx
CV events1
Schematic for illustrative purposes – not to scale
1. Source: FDA. Postmarket Drug Safety Information for Patients and Providers (Voluntarily Withdrawal of Vioxx, Sept/04 and FDA Request for Withdrawal of Bextra, April/05).

TSXV:ATE  
OTCQB:ATBPF
Our Lead Drug: ATB-346

■ Novel anti-inflammatory drug that releases hydrogen sulfide
■ Negligible GI damage: greatly superior to existing NSAIDs
■ No significant effect on blood pressure, unlike existing NSAIDs
■ Global IP with market protection to ~2030

Patents granted in major markets (including US, Europe, Japan, China & Canada)

TSXV:ATE  
OTCQB:ATBPF
Strong Phase 2B GI Safety Trial

Gastric ulcer incidence of ATB-346
■ Antibe announced successful top-line results for its versus naproxen during two-week
Phase 2B double blind GI safety study for ATB-346 in treatment period
March 2018 60
Primary endpoint was the incidence of stomach 42.1%
# of Subjects that Developed Ulcers

ulcers (>=3 mm diameter) with unequivocal depth,
considered the gold standard in assessing GI safety 45
for NSAIDs
The comparator drug was naproxen, the most
prescribed NSAID in the United States 30
■ Validation of GI safety superiority: ATB-346

exhibited an ulceration rate of 2.5% versus an 15
ulceration rate of 42.1% for naproxen over the two-
week treatment period (p<0.0001) 2.5%
0
■ ATB-346 was safe and well-tolerated ATB-346 Naproxen
*Based on comparable studies (n = 118) (n = 126)

TSXV:ATE  
OTCQB:ATBPF
Phase 2B GI Safety Trial: Secondary Endpoints

■ Strong secondary endpoints
■ Gastroduodenal ulcers and erosions

Total number of ulcers ≥3 mm: 4 for ATB-346 vs 210 for naproxen
Large ≥5 mm ulcer incidence: 0% for ABT-346 vs 24% for naproxen
Mean erosions per subject: 1.7 for ATB-346 vs 12.7 for naproxen
■ Non-GI secondary endpoints and overall safety

Thromboxane inhibition for ATB-346 was not statistically different
than naproxen (and consistent with Phase 2A results)
No blood pressure increases for ATB-346
Safe and well tolerated: overall very low incidence of adverse
events for ATB-346

TSXV:ATE  
OTCQB:ATBPF
Underway: Phase 2B Dose-Ranging, Efficacy Study

■ Final Phase 2 study for ATB-346 to validate Successful Phase 2A Efficacy Study
(completed in August 2016)
efficacy in reducing pain and set the Phase 3
Strong efficacy
dose ■
■ Once daily dosing
■ 360 osteoarthritis patients will be randomized ■ Safe and well tolerated
to either placebo or one of three doses of

ATB-346 (150 mg, 200 mg or 250 mg)
■ Enrollment expected to commence in March

2019 with a top-line data read-out anticipated
this summer 1,2
(1) Boucher, Martin. A Bayesian Meta-Analysis of Longitudinal Data in Placebo Controlled Studies with Naproxen. Pfizer.
(2) Wittenburg et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib. Arthritis Research &
Therapy Vol 8 No 2 (2004).

TSXV:ATE  
OTCQB:ATBPF
Other H2S Platform Drugs

TSXV:ATE  
OTCQB:ATBPF
ATB-352: Addressing the Opioid Crisis…

■ Antibe has commenced IND-enabling pre-clinical studies for ATB-352, a potent and
non-addictive analgesic for severe pain to address the global opioid crisis
NUMBER OF DEATHS FROM OPIOID PAIN RELIEVERS*

24,000
“
18,000
Every day, over 1,000 people are
treated in emergency departments
”
12,000
for misusing prescription opioids.
6,000 - US Department of Health and Human Services (2013)
0
1999 2001 2003 2005 2007 2009 2011 2013 2015
*United States, including non-methadone synthetics (fentanyl)
Source: National Center on Health Statistics, CDC Wonder

TSXV:ATE  
OTCQB:ATBPF
ATB-352: Potent Analgesic for Acute Pain
ATB-352, causes
negligible GI
damage in rats
compared to
ketoprofen (a very
strong NSAID
prescribed for acute
pain).
*Rat study Nitric Oxide 2014 159, 1236-1246.

TSXV:ATE  
OTCQB:ATBPF
ATB-340: A Drug For Everyone Over 50?

■ Low-dose aspirin has been known for decades to provide a dramatic reduction in the
risk of stroke and, more recently, to provide an equally dramatic reduction in the risk of
digestive system cancers (including colon cancer)
■ However, aspirin, like other NSAIDs, causes stomach ulcers and GI bleeding in an
appreciable portion of the population which precludes its broad prescription by
physicians
■ Antibe will now commence IND-enabling studies for ATB-340, a hydrogen sulfide-
releasing derivative of aspirin that has been shown to be GI-safe

TSXV:ATE  
OTCQB:ATBPF
ATB-340: Aspirin Derivative
Aspirin, but not

ATB-340, causes
significant gastric
erosions in the rat
stomach.
*Single Administration of test drugs to rats

TSXV:ATE  
OTCQB:ATBPF
Commercial Asset in  
Regenerative Medicine

Applications
DynaGraft·D
DynaGraft·D™ TSXV:ATE  
- (gel) 10-110-1050 • Periodontal defects
(gel) 10-110-1060
• Extraction site repair DBM RPM
OTCQB:ATBPF
y) 10-120-1050
• Implant site development
• Sinus lift procedures
tty) 10-120-1060
• Coronal defects around immediate implants
Demineralized bone matrix with cancellous bone

DynaBlast™ is a composite graft product that combines osteoinductive and osteoconductive elements in a proprietary,
Citagenix: Poised for Global Growth…

reverse phase medium for superior handling.
DynaBlast™ Applications
- (paste) 10-210-1050 DynaBlast
(paste) 10-210-1060 DBM RPM
• Extraction site repair
(paste) 10-210-1070 • Implant dehiscence defects
■ Our commercial subsidiary, Citagenix Inc. (“Citagenix”), is the market leader in Canada
y) 10-220-1030 • Sinus lift procedures
tty) 10-220-1040 • Moderate localized ridge defects CANCELLOUS
in dental
Demineralized regenerative
bone matrix putty medicine and is poised for global growth
Accell Connexus is a high surface area demineralized bone matrix (ABM) that incorporates a highly biocompatible
Reverse Phase Medium (RPM) for robust handling.
efits Applications
Citagenix has a $10M1 revenue base and
oinductive potential Accell Connexus hasRPMinitiated a global growth strategy
DBM
Regenerative medicine is
s at body temperature • When the highest level of growth factors is desired
tion • Osseous defects growing globally at 30%+3
• In combination with less osteoinductive materials
ABM
Accell Connexus®
• Implant site preparation or repair
- (putty) 10-310-1050
(putty) 10-310-1060 Bone Graft Substitutes
Synthetic resorbable bone substitute Dental Barrier Membranes

Synthetic resorbable bone substitute that uses the mineral building blocks naturally found in human bone. Eclipse™
goes a step beyond with its unique combination of micro and macroporosity technology. High Quality Instruments
Granules: 80% ß-tcp - 20% HA — Putty: 40% ß-tcp - 60% HA
pse™ Granules 0.5 to 1.0 mm Applications BMT BMT
E1G002 • Ridge preservation GUIDED BONE BD-30 GUIDED TISSUE

— REGENERATION KIT — — REGENERATION KIT — BS-60
E1G005 • Extraction site repair BS-60
E1G010 • Sinus lifts SS-65
• Ridge augmentation
Global Market
US$700
e) E1GS005
syringes in a single sterile package) E1GS010
• Osseous defects 100-C15
BB-46 MA-B1
• Periodontal defects
pse™ Granules 1.0 to 2.0 mm
E2G020 SERRATED
FG-1SCZ
for Oral Tissue
LB-364 ES-13
MILLION
FG-1SCZ FG-2SCZ MA-B1 MO-10 718-107 BD-158 707-2311
Eclipse™ Putty 40 | 60 LS-08 SERRATED
Regeneration2
IM-15
SHARP
MIR-08
SHARP
OBN-4 FG-2SCZ
e) E1P005 BD-158
BD-30
inges in separate sterile packages) E1P010 Eclipse™ SHARP LB-367
FD-170
May be used alone or mixed with DBM
Putty for osteoinductive potential. TUNGSTEN
CARBIDE
TUNGSTEN
CARBIDE
PH-79 LB-369
100-C15
(1) Annualized sales run rate based on the three month period ended December 31,
PH-79 Needle 2018
Holder, 145 mm MO-10 Surgical Curette BD-30 Tissue Forceps MA-B1 Scalpel handle
ft (2)
Substitutes FG-1SCZ Iris Super-Cut scissors, Straight
Source: Straumann 2016 Annual Report (page 53) assuming USD:CHF FX rate of 1.00 : 1.00 MIR-08 Periosteal Raspatory 7 LS-08 Ruler ES-13 Dissector
FG-2SCZ Iris Super-Cut scissors, Curved 718-107 Periodontal Chisel 100-C15 Scalpel blades 707-2311 Double-ended explorer
(3) Source: BCC Research LLC, September 2016 100-C15 Scalpel Blades OBN-4 Gingivectomy Knives FG-1SCZ Iris Super-Cut scissors, Straight BS-60 Tray for 10 instruments
SS-65 Stainless steel bone well, Ø 35 mm BD-158 Micro Suture and Membrane Forceps FG-2SCZ Iris Super-Cut scissors, Curved FD-170 Needle holder
!18
MA-B1 #5 Scalpel Handle BD-30
Tissue Forceps BB-46 Micro scalpel handle BD-158 Micro suture and membrane forceps
IM-15 Applicator for Bone Material BS-60 Tray for 10 instruments LB-364, 367, 369 Micro blades
TSXV:ATE  
OTCQB:ATBPF
Corporate Information

TSXV:ATE  
OTCQB:ATBPF
Leadership Team & Board
Leadership Board of Directors

■ Dan Legault JD  ■ Walt Macnee MBA Chairman 
CHIEF EXECUTIVE OFFICER
VICE CHAIRMAN / MASTERCARD INC.
■ John Wallace PhD, MBA   ■ Roderick Flower PhD 

CHIEF SCIENTIFIC OFFICER
EMERITUS PROFESSOR OF PHARMACOLOGY / WILLIAM
HARVEY RESEARCH INSTITUTE (WHRI)
■ Alain Wilson MBA 
CHIEF FINANCIAL OFFICER ■ Amal Khouri MBA 
VP, BUSINESS DEVELOPMENT / KNIGHT THERAPEUTICS INC.
■ David Vaughan PhD 
CHIEF DEVELOPMENT OFFICER ■ Dan Legault JD 
CHIEF EXECUTIVE OFFICER / ANTIBE THERAPEUTICS INC.
■ Michael McMillan 
CHIEF EXECUTIVE OFFICER / CITAGENIX INC. ■ John Wallace PhD, MBA  
CHIEF SCIENTIFIC OFFICER / ANTIBE THERAPEUTICS INC.
■ Scott Curtis MEng, CFA  
VP, CORPORATE DEVELOPMENT ■ Yung Wu  
CHIEF EXECUTIVE OFFICER / MARS DISCOVERY DISTRICT

TSXV:ATE  
OTCQB:ATBPF
Business Development Advisory Board

■ Angus Russell CA ■ Andrew Powell JD
Former CEO of Shire (2008 - 2013); led Played instrumental role in the sale of: Medivation
expansion into new therapeutic areas through a to Pfizer for US$14B; InterMune to Roche for
series of late-stage deals US$8.3B; ImClone to Eli Lilly for US$6.5B
Currently Chairman of Mallinckrodt, a leading Currently a director at Aclaris Therapeutics, a

global specialty pharma company biopharma company focused on dermatology
■ Dominique Monnet MBA ■ Rami Batal PhD, MBA

Responsible for accelerating growth of Amgen’s Former VP, Business Development for Purdue
Inflammation division and its Enbrel® franchise Canada; brings to Antibe vast experience in the
pain markets
Currently President of PDL BioPharma, a
manager of healthcare companies, products Currently VP, Medical Research of Canopy Growth,
and royalties a leading cannabis producer and innovator

TSXV:ATE  
OTCQB:ATBPF
World-Class Scientific Advisors

■ Dr. Andre Buret PhD  ■ Dr. Jane A. Mitchell PhD  
Our clinical and CALGARY, ALBERTA LONDON, ENGLAND
scientific advisory ■ Dr. Francis Chan MD, PhD   ■ Dr. Gilberto de Nucci MD, PhD 
HONG KONG, CHINA SAO PAOLO, BRAZIL
boards are
■ Dr. Giuseppe Cirino PhD   ■ Dr. Daniel K. Podolsky MD 
comprised of world- NAPLES, ITALY DALLAS, TEXAS
class scientists, ■ Dr. Peter B. Ernst DVM, PhD  ■ Dr. James Scheiman BS, MD 
including a Nobel
SAN DIEGO, CALIFORNIA ANN ARBOR, MICHIGAN
■ Dr. Derek Gilroy PhD  ■ Dr. William Sessa PhD 

Laureate. LONDON, ENGLAND NEW HAVEN, CONNECTICUT
■ Dr. Richard H. Hunt MD   ■ Dr. Philip M. Sherman MD 

OXFORD, ENGLAND TORONTO, ONTARIO
■ Dr. Louis J. Ignarro PhD  ■ Dr. J. Carter Thorne MD, FRCP(C), FACP 
LOS ANGELES, CALIFORNIA NEWMARKET, ONTARIO
■ Dr. Angel Lanas MD, DSc 

ZARAGOZA, SPAIN

TSXV:ATE  
OTCQB:ATBPF
Capitalization Summary
Stock Symbols TSXV-ATE; OTCQB-ATBPF
$0.70 20,000
Share Price(1) $0.27
18,000
$0.60
Shares Outstanding 243M 16,000
$0.50 14,000
Stock Options & RSUs 35M
Volume (thousands)
Share Price (CAD)
12,000
$0.40
Warrants 33M
10,000
$0.30
Market Capitalization(1) $66M 8,000
$0.20 6,000
Cash & Equivalents(2) $8M
4,000
$0.10
Insider Ownership FULLY DILUTED 20% 2,000
Annual Sales(3) $10M Feb-18 May-18 Jul-18 Sep-18 Dec-18 Feb-19
(1) As of market close February 25, 2019

(2) As at the end of Q3/F19 reporting period (December 31, 2018) with the addition of net proceeds from February 2019 prospectus offering
(3) Annualized sales run rate based on the three month period ended December 31, 2018

TSXV:ATE  
OTCQB:ATBPF
Key Takeaways
■ Best-in-class drug platform: Antibe’s proprietary hydrogen sulfide (“H2S”) technology
represents a game-changing medical advance in the safe treatment of pain & inflammation
■ Strong Phase 2 proof-of-concept data: Antibe’s lead drug, ATB-346, recently showed
superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate)
■ Phase 2 dose-ranging, efficacy study underway: will provide a robust package of efficacy
and metabolism data for regulatory bodies and global partners
■ Potential to disrupt global pain market: the global pain market, including opioids, exceeds
$20 billion and would benefit greatly from GI-safe and non-addictive therapies
■ Commercial asset in regenerative medicine: Antibe’s subsidiary, Citagenix, is poised for

growth in the dental biologics market with a revenue base of $10 million1
■ Seasoned management team, Board of Directors and advisors
(1) Annualized sales run rate based on the three month period ended December 31, 2018

TSXV:ATE  
OTCQB:ATBPF
Appendix  
H2S Platform: Rooted by Strong Science

TSXV:ATE  
OTCQB:ATBPF
H2S: Anti-inflammatory & Cytoprotective

Hydrogen sulfide Rolling
NRF2–KEAP1 H2S
(“H2S”) has become

Adhesion pathway
Resolution of inﬂammation
H2 S
recognized as a crucial NRF2 KEAP1
signalling molecule
M1 M2 • Inhibits leukocyte–
endothelial cell adhesion
• Reduces oedema formation
Dissociation
NRF2
with a wide range of

↓NFκB activation Pro-inﬂammatory Repair from KEAP1
cytokines
anti-inflammatory and H2S NFκB

Hydrogen sulphide
Transcriptionally
active complex NRF2 MAF
Gene
transcription
cytoprotective mRNA
ARE
functions. Antioxidant
PDE
e e e
e HS e e e Vasodilation
2 Neutrophil apoptosis
e e e e
e e e e e
ATP generation
ATP
Analgesic
Nature Reviews | Drug Discovery
Source: Wallace & Wang, Nature Reviews Drug Discovery 2015; 14,329-345.

TSXV:ATE  
OTCQB:ATBPF
H2S physiological activities reduce inflammation in the

H S Prevents NSAID-Induced Injury
2
gastrointestinal (“GI”) tract and prevent NSAID-induced injury.
H2S physiological activities reduce

inflammation in the gastrointestinal (“GI”)
tract and prevent NSAID-induced injury.
Source: (left) Wallace & Wang, Nature Reviews Drug Discovery 2015; 14,329-345. (right) Gemici et al.,
Nitric Oxide 46 (2015) 25–31.

TSXV:ATE  
OTCQB:ATBPF
Superior GI Safety Over Existing NSAIDs
ATB-346 produces
negligible GI
damage over the full
dosing range, unlike
comparator NSAIDs.
*Rat study Br J Pharmacol 2010; 159,1236-1246.

TSXV:ATE  
OTCQB:ATBPF
Rigorous Testing of GI Safety
In conditions of
increased
susceptibility to
gastric damage, the
GI damage from
comparator NSAIDs
significantly increases
whereas ATB-346
remains GI-safe.

TSXV:ATE  
OTCQB:ATBPF
Additional Models Tested
Impaired Mucosal Defence Co-Morbidity

■ Sensory afferent nerves ■ Obesity
■ Inhibition of endogenous nitric ■ Advanced age

oxide
■ Rheumatoid arthritis
■ Inhibition of endogenous
■ Hypertension
hydrogen sulphide
■ Blockage of ATP-mediated ■ Pre-existing ulcers [healing]
potassium channel

TSXV:ATE  
OTCQB:ATBPF
No Significant Effect on Blood Pressure
Unlike other NSAIDs,

ATB-346 does not
significantly increase 15
blood pressure; this
result was confirmed Mean Arterial Pressure (mmHg)
in both the Phase 1 10
and Phase 2 studies.

5
0
Vehicle Naproxen ATB-346

TSXV:ATE  
OTCQB:ATBPF
Leading Innovation in Pain & Inflammation

FEBRUARY 2019
Thank you!
For more information, please contact:
Dan Legault, CEO  
dan@antibethera.com

Antibe Investor Presentation - February 2019

Diunggah oleh

Informasi Dokumen

Hak Cipta

Bagikan dokumen Ini

Bagikan atau Tanam Dokumen

Opsi Berbagi

Apakah menurut Anda dokumen ini bermanfaat?

Apakah konten ini tidak pantas?

Hak Cipta:

Antibe Investor Presentation - February 2019

Diunggah oleh

Hak Cipta:

TSXV:ATE

Leading Innovation in Pain & Inflammation

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com -

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !2

Antibe Therapeutics (“Antibe”) is a

Antibes Seen from the Salis Gardens Claude Monet (1840-1926)

Stock Symbols TSXV-ATE; OTCQB-ATBPF Shares Outstanding 243M

52 Week Trading Range $0.24 - $0.79 Market Capitalization $66M

Avg. Daily Volume* 562,000 Insider Ownership FULLY DILUTED 20%

*average of TSX-V daily volume over last 3 months

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !3

ATB-346: Lead Drug

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !4

NSAIDs: Large Market Opportunity

NSAIDs = Non-Steroidal $11 Billion

“The world needs a safer A Global

1. Global sales in 2014 (Evaluate Pharma)

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !5

NSAIDs Have a Blockbuster Pedigree

safety from NSAIDs Product Company

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !6

Addressing an Unmet Need…

ATB-346 was Better CV Safety

Schematic for illustrative purposes – not to scale

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !7

Our Lead Drug: ATB-346

■ Negligible GI damage: greatly superior to existing NSAIDs

■ No significant effect on blood pressure, unlike existing NSAIDs

■ Global IP with market protection to ~2030

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !8

Strong Phase 2B GI Safety Trial

# of Subjects that Developed Ulcers

■ Validation of GI safety superiority: ATB-346

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !9

Phase 2B GI Safety Trial: Secondary Endpoints

■ Gastroduodenal ulcers and erosions

■ Non-GI secondary endpoints and overall safety

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !10

Underway: Phase 2B Dose-Ranging, Efficacy Study

■ Once daily dosing

■ 360 osteoarthritis patients will be randomized ■ Safe and well tolerated

to either placebo or one of three doses of

■ Enrollment expected to commence in March

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !11

Other H2S Platform Drugs

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !12

ATB-352: Addressing the Opioid Crisis…

NUMBER OF DEATHS FROM OPIOID PAIN RELIEVERS*

Source: National Center on Health Statistics, CDC Wonder

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !13

ATB-352: Potent Analgesic for Acute Pain

*Rat study Nitric Oxide 2014 159, 1236-1246.

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !14

ATB-340: A Drug For Everyone Over 50?

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !15

ATB-340: Aspirin Derivative

Aspirin, but not

*Single Administration of test drugs to rats

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !16

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !17

Demineralized bone matrix with cancellous bone

Citagenix: Poised for Global Growth…

Synthetic resorbable bone substitute Dental Barrier Membranes

pse™ Granules 0.5 to 1.0 mm Applications BMT BMT

E1G002 • Ridge preservation GUIDED BONE BD-30 GUIDED TISSUE

E1G010 • Sinus lifts SS-65

Antibe Therapeutics Inc. ■ February 2019 - www.antibethera.com - !19

TSXV:ATE  

NSAIDs = Non-Steroidal   $11 Billion

■ John Wallace PhD, MBA   ■ Roderick Flower PhD 

■ Dr. Derek Gilroy PhD  ■ Dr. William Sessa PhD 

■ Dr. Richard H. Hunt MD   ■ Dr. Philip M. Sherman MD 

■ Dr. Angel Lanas MD, DSc 